The Food and Drug Administration (FDA) began reviews this month on three new weight loss drugs. The first to be reviewed, Qnexa developed by Vivus Inc., which is a mixture of two existing drugs, an anticonvulsant (topiramate) and an amphetamine (phentermine).
More:
Next Weight Loss Drug on FDA Agenda: Contrave